Get the latest stock ideas direct to your inbox. 100% free and your information stays with us.
The health scare has only accelerated the global demand for medication.
In fact, according to Fortune Business Insights, in 2020, the health scare “accelerated the demand for effective treatments and drugs worldwide” and caused the global pharmaceutical industry to reach an estimated valuation of $1.3 Trillion.(2)
In addition, they noted there’s an “increasing prevalence of chronic disease and the growing adoption of modern technologies that are leading to the evolving pharmaceuticals sector.”
This is why Fortune believes we could see the global pharmaceuticals market size reach nearly $2.15 trillion by 2027 at an estimated CAGR of 7.0%.(3)
Where Cosmos Holdings (NASDAQ: COSM) Fits
One of the top companies benefiting from this pharma rush is Cosmos Holdings (NASDAQ COSM). Cosmos is a disruptive company that offers customers and shareholders diversified exposure to several in-demand and growing verticals in the pharma and wellness space, including:(4)
Clearly, Cosmos and its unique business model may be doing something right.
Not only did Cosmos see 2020 revenue growth of about 40% and jaw-dropping gross profit growth of nearly 120%,(9) it reported 15.8% year-over-year growth and a 27.8% sequential increase in revenue for Q2 2021.(1)
But that’s not the company’s biggest news at the moment…
In a major company milestone, Cosmos just uplisted to the Nasdaq Capital Market!(10)
Why is this so huge? Easy. When a company uplists to a major exchange, there typically comes a significant amount of added visibility and exposure for them to bask in.
Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated,
"We are very excited to announce our listing on Nasdaq, which is a major milestone to drive further opportunities to scale our business and expand our distribution network worldwide for our proprietary lines of nutraceuticals as well as third-party branded pharmaceuticals.”(10)
The best part of all of this? It may only be the start of more game-changing company developments to come…
The company is focused on identifying, acquiring, developing, and commercializing different medicines to improve patients’ lives. Cosmos has an extensive network of over 160 clients and vendors in Germany, the United Kingdom, United Arab Emirates, Denmark, Italy, France, Singapore, Ireland, Sweden, Poland, Netherlands, and Greece.(8) Not to mention, Cosmos has offices and distribution centers in Thessaloniki, Greece, and Harlow, UK.(8)
Even more impressive is how quickly the company is growing. On top of the company’s massive earnings growth, CEO Greg Siokas recently said:
“We are rapidly expanding our distribution network worldwide and opening new markets for our proprietary line of branded pharmaceuticals, nutraceuticals, and food supplements.
We entered into an exclusive distribution agreement with Mediprovita GbR (Mediprovita) for the distribution of our full line of proprietary nutraceuticals, Sky Premium Life, in Germany and Austria. Mediprovita has over 25 years of expertise in e-commerce and a successful track record in selling health products.” (1)
Additionally, the company “entered into a three-year distribution agreement with China-based REMAI e-Commerce Co., Ltd. (REMAI) to open a flagship store and launch our Sky Premium Life products on Alibaba’s Tmall Global, the world’s largest cross-border e-commerce marketplace with 500 million monthly active users.”(1)
Plus, according to the CEO, over the past three months, Cosmos began reducing its debt and has now converted $5.25 million of it to equity.(1)
A few months back, Cosmos made a HUGE announcement in regards to installing a “State-of-the-Art” automated fulfillment system at their logistics center in Greece.
The fully automated fulfillment system is designed to process complex orders with precision and speed, leading to increased performance while drastically lowering error rates.
The system can process up to 40,000 products per hour and can accommodate a variety of packaging shapes and sizes.
Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated,
“With a fully robotic system in place, CosmoFarm’s logistic center can now process orders at higher speeds and higher quality, even at peak times. This is critical to maintain the quality of our service while scaling our product offerings and client base. This installation reflects our commitment to invest in advanced technologies that substantially expand our current productivity and throughput, supporting our growth and improving the overall efficacy of our deliverables.” (11)
CosmoFarm, headquartered in Athens, Greece is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. CosmoFarm’s core activity is sourcing, procuring, and distributing branded and generic medicines, over-the-counter (OTC) pharmaceuticals, food supplements, and medical devices to its growing network of more than 1,130 pharmacies.
The foundation of Cosmos’ operating strategy is the optimization and growth of its pharmaceutical sourcing and distribution businesses. As Cosmos continues devoting significant resources to improve its operating and capital efficiencies, it believes it’s well-positioned in size and breadth to continue growing its trading businesses.
Sourcing and distribution, including specialty pharmaceuticals, is what Cosmos sees as the anchor of its growth and position in the pharmaceutical supply channel. Cosmos provides superior services and delivers value-added products, which improve the efficiency and competitiveness of healthcare providers. In turn, this aids the pharmaceutical supply channel to better provide healthcare to patients.
Get the latest stock ideas direct to your inbox.
100% free and your information stays with us.
Specific areas of Cosmos (NASDAQ: COSM) focus include the following: (7)
Sky Pharm SA is a Thessaloniki, Greece-based pharmaceutical trading firm. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. Cosmos buys from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers and then exports them to European markets where demand and prices are substantially higher.
Decahedron Ltd. is a UK-incorporated pharmaceutical wholesaler. It is audited by the MHRA under European GDP (Good Distribution Practices). It is also a full member of the EAEPC and has been audited by TÜV on its behalf. Decahedron imports and exports branded, generic and unlicensed POM, OTCs, and medical devices worldwide. It also participates in governmental tenders and registers dossiers in new territories. This subsidiary’s network consists of roughly 25 clients and vendors expanding to 9 countries, including Germany, UK, Denmark, United Arab Emirates, Germany, Italy, France, Singapore, and Ireland.
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area.
Source 2: https://bit.ly/3sTk48z
Source 3: https://bit.ly/3vnYLh4
Source 4: https://www.cosmosholdingsinc.com/company/strategy
Source 5: https://finance.yahoo.com/news/cosmos-holdings-secures-approximately-5-131500199.html
Source 6: https://www.barchart.com/stocks/quotes/COSM/interactive-chart
Source 7: https://www.cosmosholdingsinc.com/company/strategy
Source 8: https://www.cosmosholdingsinc.com
Source 9: https://www.globenewswire.com/en/news-release/2021/04/16/2211656/0/en/Cosmos-Holdings-Reports-Revenue-Growth-of-40-to-a-Record-55-4-Million-and-Achieves-Profitability-for-2020.html
Source 10: https://finance.yahoo.com/news/exchange-listing-client-cosmos-holdings-130000890.html
Source 11: https://finance.yahoo.com/news/cosmos-holdings-announces-installation-state-141100752.html
Stock Research Today is a project of Dadmin Capital LLC and intended solely for entertainment and informational purposes. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/. This website / media webpage is owned, operated and edited by Dadmin Capital LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Dadmin Capital” refers to Dadmin Capital LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage .We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Dadmin Capital business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Dadmin Capital. often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Compensation – Pursuant to an agreement between Dadmin Capital LLC and TD Media LLC, Dadmin Capital LLC has been hired for a period beginning on 3/23/22 and ending after 2 business days to publicly disseminate information about (NASDAQ: COSM) via digital communications. We have been paid eleven thousand five hundred USD via ACH Bank Transfer.